Full Title:
Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) - the PATH study Protocol IgPro20_3003
Specialty:
- Peripheral Neuropathy Center
Status:
- Open for Enrollment
Principle Investigator:
Norman Latov, MD, PhD Contact Phone :
(646) 962-2149 Additional Cornell Investigator:
Russell L. Chin, MD Jennifer A. Langsdorf, MD 
To read more about this study visit the ClinicalTrials.gov page here.